دورية أكاديمية
أعرض في EDS

Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.

التفاصيل البيبلوغرافية
العنوان: Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination.
المؤلفون: Lee PH; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.; Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung 402, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan., Ou WF; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan., Huang YH; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan.; Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung 407, Taiwan., Hsu KH; Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung 407, Taiwan.; Division of Critical Care and Respiratory Therapy, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan., Tseng JS; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.; School of Medicine, National Yang Ming Chiao Tung University, Taipei 112, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan.; Lung Cancer Comprehensive Care and Research Center, Taichung Veterans General Hospital, Taichung 407, Taiwan.; Department of Post-Baccalaureate Medicine, College of Medicine, National Chung Hsing University, Taichung 402, Taiwan., Chang GC; Division of Pulmonary Medicine, Department of Internal Medicine, Chung Shan Medical University Hospital, Taichung 402, Taiwan.; School of Medicine, Chung Shan Medical University, Taichung 402, Taiwan.; Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan., Yang TY; Division of Chest Medicine, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung 407, Taiwan.; Doctoral Program in Translational Medicine, National Chung Hsing University, Taichung 402, Taiwan.; Rong Hsing Translational Medicine Research Center, National Chung Hsing University, Taichung 402, Taiwan.; Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan.; Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan.
المصدر: International journal of molecular sciences [Int J Mol Sci] 2024 Jun 25; Vol. 25 (13). Date of Electronic Publication: 2024 Jun 25.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI, [2000-
مواضيع طبية MeSH: High-Throughput Nucleotide Sequencing*/methods , Adenocarcinoma of Lung*/genetics , Adenocarcinoma of Lung*/pathology , Adenocarcinoma of Lung*/mortality , Lung Neoplasms*/genetics , Lung Neoplasms*/mortality , Lung Neoplasms*/pathology , Lung Neoplasms*/drug therapy , Mutation*, Humans ; Male ; Female ; Middle Aged ; Aged ; Adult ; Aged, 80 and over
مستخلص: Despite the widespread application of next-generation sequencing (NGS) in advanced lung adenocarcinoma, its impact on survival and the optimal timing for the examination remain uncertain. This cohort study included advanced lung adenocarcinoma patients who underwent NGS testing. We categorized patients into four groups: Group 1: treatment-naïve, upfront NGS; Group 2: Treatment-naïve, exclusionary EGFR / ALK / ROS1 ; Group 3: post-treatment, no known EGFR / ALK / ROS1 ; Group 4: known driver mutation and post-TKI treatment. A total of 424 patients were included. There were 128, 126, 90, and 80 patients in Groups 1, 2, 3, and 4, respectively. In Groups 1, 2, 3, and 4, targetable mutations were identified in 76.6%, 49.2%, 41.1%, and 33.3% of the patients, respectively ( p < 0.001). Mutation-targeted treatments were applied in 68.0%, 15.1%, 27.8%, and 22.5% of the patients, respectively ( p < 0.001). In the overall population, patients receiving mutation-targeted treatments exhibited significantly longer overall survival (OS) (aHR 0.54 [95% CI 0.37-0.79], p = 0.001). The most profound benefit was seen in the Group 1 patients (not reached vs. 40.4 months, p = 0.028). The median OS of patients with mutation-targeted treatments was also significantly longer among Group 2 patients. The median post-NGS survival of patients receiving mutation-targeted treatments was numerically longer in Group 3 and Group 4 patients. In conclusion, mutation-targeted therapy is associated with a favorable outcome. However, the opportunities of NGS-directed treatment and the survival benefits of mutation-targeted treatment were various among different populations.
Competing Interests: The authors declare no conflicts of interest.
References: ESMO Open. 2024 Jan;9(1):102200. (PMID: 38194884)
Cancer. 2020 Jan 15;126(2):373-380. (PMID: 31769875)
N Engl J Med. 2020 Aug 13;383(7):640-649. (PMID: 32786189)
J Thorac Oncol. 2014 Feb;9(2):154-62. (PMID: 24419411)
J Thorac Oncol. 2021 Oct;16(10):1647-1662. (PMID: 34246791)
Clin Lung Cancer. 2022 Nov;23(7):e443-e452. (PMID: 35902325)
Ann Oncol. 2015 Jul;26(7):1415-21. (PMID: 25922063)
Clin Transl Med. 2017 Dec;6(1):6. (PMID: 28101783)
Ann Oncol. 2023 Apr;34(4):339-357. (PMID: 36872130)
Lancet Oncol. 2017 Jul;18(7):874-886. (PMID: 28602779)
J Natl Compr Canc Netw. 2023 Apr;21(4):340-350. (PMID: 37015337)
Transl Lung Cancer Res. 2019 Nov;8(Suppl 3):S265-S279. (PMID: 31857950)
Clin Respir J. 2022 Mar;16(3):216-225. (PMID: 35081265)
Anticancer Res. 2023 Jun;43(6):2771-2776. (PMID: 37247929)
Mol Oncol. 2023 Feb;17(2):230-237. (PMID: 36269676)
Cancers (Basel). 2022 May 10;14(10):. (PMID: 35625958)
EClinicalMedicine. 2023 Jun 01;60:102029. (PMID: 37304496)
JCO Precis Oncol. 2023 Jun;7:e2200715. (PMID: 37285561)
J Thorac Oncol. 2016 Dec;11(12):2129-2140. (PMID: 27615396)
JAMA. 2014 May 21;311(19):1998-2006. (PMID: 24846037)
Ann Oncol. 2020 Nov;31(11):1536-1544. (PMID: 32861806)
J Clin Oncol. 2019 Jun 1;37(16):1370-1379. (PMID: 30892989)
N Engl J Med. 2013 Jun 20;368(25):2385-94. (PMID: 23724913)
PLoS One. 2015 Mar 19;10(3):e0120852. (PMID: 25789627)
CA Cancer J Clin. 2023 Jan;73(1):17-48. (PMID: 36633525)
Sci Rep. 2022 Aug 9;12(1):13566. (PMID: 35945330)
JCO Precis Oncol. 2020 Nov;4:1038-1048. (PMID: 35050771)
Br J Cancer. 2019 Oct;121(9):725-737. (PMID: 31564718)
J Thorac Oncol. 2023 Apr;18(4):436-446. (PMID: 36379356)
Cancer Manag Res. 2023 Nov 16;15:1307-1318. (PMID: 38027245)
J Thorac Oncol. 2006 Jul;1(6):520-5. (PMID: 17409911)
Cancer Discov. 2023 Jan 9;13(1):98-113. (PMID: 36264123)
J Thorac Oncol. 2021 Apr;16(4):519-527. (PMID: 33781442)
فهرسة مساهمة: Keywords: adenocarcinoma; driver mutation; lung cancer; next-generation sequencing (NGS); targeted therapy
تواريخ الأحداث: Date Created: 20240713 Date Completed: 20240713 Latest Revision: 20240715
رمز التحديث: 20240715
مُعرف محوري في PubMed: PMC11241057
DOI: 10.3390/ijms25136949
PMID: 39000058
قاعدة البيانات: MEDLINE
الوصف
تدمد:1422-0067
DOI:10.3390/ijms25136949